10-Q/A: BioRegenx Restates Q1 2024 Financials Following Auditor Change and Merger

BioRegenx, Inc. has filed an amended quarterly report for Q1 2024, restating its financials due to a change in auditors and adjustments related to recent acquisitions and a merger.

Summary

• BioRegenx, Inc. has restated its financial statements for the three months ended March 31, 2024, and 2023, due to a change in independent accountants and the discovery of errors in previous filings.
• The company incurred a net loss of $3,152,458 for the quarter ended March 31, 2024, compared to a net loss of $229,838 for the same period in 2023.
• Net sales decreased by 49% to $549,548 in Q1 2024, down from $1,075,585 in Q1 2023, primarily due to product issues and a resulting equity refund offer.
• Operating expenses increased significantly to $3,463,594 in Q1 2024, up from $947,997 in Q1 2023, driven by equity compensation and increased legal and professional costs.
• The company's cash and cash equivalents decreased to $114,158 as of March 31, 2024, from $125,402 at the end of 2023.
• BioRegenx completed the acquisition of DocSun Biomedical Holdings, Inc. on January 8, 2024, for $10,656,000 in stock and a $150,000 deposit.
• A merger with Findit, Inc. was completed on March 8, 2024, resulting in a change of control and the company name changing to BioRegenx, Inc.
• The company has a working capital deficit of $2,899,223 and an accumulated deficit of $15,670,436 as of March 31, 2024.
• Notes payable of $522,500 were in default as of March 31, 2024.
• The company's management has concluded that there is substantial doubt about the company's ability to continue as a going concern.

Sentiment

Score: 2

Explanation: The document reveals significant financial challenges, including substantial losses, declining sales, and a going concern warning, indicating a very negative outlook from an investment perspective.

Positives

• The company completed the acquisition of DocSun Biomedical Holdings, Inc., which is expected to expand its product line.
• The merger with Findit, Inc. has resulted in a new corporate structure and a change in the company's name to BioRegenx, Inc.

Negatives

• The company experienced a significant decrease in net sales and an increase in returns due to product issues.
• Operating expenses have increased substantially, primarily due to equity compensation and professional fees.
• The company has a significant working capital deficit and an accumulated deficit.
• A substantial amount of notes payable are in default.
• Management has expressed substantial doubt about the company's ability to continue as a going concern.

Risks

• The company's ability to continue as a going concern is dependent on obtaining additional debt or equity financing.
• The company faces risks related to its ability to generate positive cash flow.
• The company is involved in disputes with certain parties, including former officers and board members.
• The company has identified material weaknesses in its internal control over financial reporting.
• The company has a history of recurring losses from operations and cash flow deficits.

Future Outlook

The company anticipates it will require additional capital in order to develop its business and may use a combination of equity and/or debt instruments or enter into a strategic arrangement with a third party. Management has yet to find a solution to its funding requirements.

Management Comments

• Management has concluded that there is substantial doubt about the company's ability to continue as a going concern.
• Management intends to raise additional debt or equity financing to fund ongoing operations and for necessary working capital.

Industry Context

The company operates in the medical device and nutritional product sectors, which are subject to regulatory approvals and market competition. The company's financial performance is impacted by product issues and the need for additional capital.

Comparison to Industry Standards

• It is difficult to make a direct comparison to industry standards without more specific information about the company's niche within the medical device and nutritional product sectors.
• However, the company's significant losses, declining sales, and substantial doubt about its ability to continue as a going concern are concerning and indicate that the company is underperforming compared to industry benchmarks.
• The company's financial performance is significantly worse than comparable companies in the medical device and nutritional product sectors, which typically have more stable revenue streams and lower operating expenses.
• The company's reliance on debt and equity financing to fund operations is also a concern, as it indicates a lack of sustainable revenue generation.

Legal Proceedings

• The company is involved in disputes with certain parties, including former officers and board members and vendors associated with their activities.

Related Party Transactions

• The company rents its home office from BBD Holdings, LLC, which is controlled by an officer and director.
• The company sells a product subject to a royalty agreement with the VHS Pool, in which an officer and director has a creditor interest.
• The company has a worldwide distribution agreement with GlycoCheck B.V., where directors of BioRegenx also have an interest.
• The company reimburses certain officers for company expenses paid through individual accounts.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and going concern warning.
• Employees may be impacted by potential cost-cutting measures or restructuring.
• Customers may experience disruptions in product availability or support due to the company's financial challenges.
• Suppliers and creditors face increased risk of non-payment due to the company's financial difficulties.

Next Steps

• The company intends to raise additional debt or equity financing to fund ongoing operations.
• The company will continue to work on integrating the acquired DocSun Biomedical Holdings, Inc. and the merged Findit, Inc.
• The company will need to address the material weaknesses in its internal control over financial reporting.

Key Dates

Keywords

BioRegenx, financial restatement, merger, acquisition, DocSun Biomedical, Findit, going concern, net loss, operating expenses, working capital, debt default, internal control, equity compensation, medical devices, nutritional products